rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Silexion Therapeutics Corp -

SLXN · Nasdaq

Health CareBiotechnologyNot moving yet

SLXN stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 96.3% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$62K
Officials’ trades on record
0
Institutions holding
16 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$60K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
Mitchell ShirvanCSO and CDOsold22,818at $1.3626 Mar 2026filed 30 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders16+0 on the quarter
New · exited1 · 1
Reported value$64K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Polar Asset Management Partners Inc.unchanged · filed 14 Aug 2026743,475$21K00.0%
Linden Advisors LPunchanged · filed 14 Aug 2026337,500$9,48400.0%
ARISTEIA CAPITAL, L.L.C.unchanged · filed 14 Aug 2026236,546$6,63500.0%
Clear Street Group Inc.reduced · filed 12 Aug 2026218,165$6,632-600−0.3%
SECURITY BENEFIT LIFE INSURANCE COunchanged · filed 21 Jul 2026150,000$1,87500.0%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026125,103$3,803+1,609+1.3%
SUSQUEHANNA INTERNATIONAL GROUP, LLPnew · filed 14 Aug 202692,073$2,799+92,073
JANE STREET GROUP, LLCunchanged · filed 14 Aug 202674,910$2,27700.0%
PICTON MAHONEY ASSET MANAGEMENTunchanged · filed 13 Aug 202657,175$1,73800.0%
Context Capital Management, LLCunchanged · filed 23 Jul 202651,183$1,55600.0%
30 Sep 2024 – 30 Jun 2026
162126Sep 24Mar 25Sep 25Dec 25Jun 26

Everyone who traded it

Hadar Mirit Horenshtein Company insiderCFO and Secretary · last 4 Jun 20260 · 0
Ilan Hadar Company insiderChairman and CEO · last 4 Jun 20260 · 0
Mitchell Shirvan Company insiderCSO and CDO · last 4 Jun 20260 · 1
Amnon Peled Company insiderDirector · last 20 Feb 20260 · 0
Avner Lushi Company insiderDirector · last 20 Feb 20260 · 0
Dror Yosef Abramov Company insiderDirector · last 20 Feb 20260 · 0
Ruth Alon Company insiderDirector · last 20 Feb 20260 · 0
Shlomo Noy Company insiderDirector · last 20 Feb 20260 · 0
Ilan Levin Company insiderDirector, 10% owner · last 15 Sep 20250 · 0
Moringa Sponsor, Lp Company insider10% owner · last 15 Sep 20250 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 10 Mar 20266.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$6.0M
Free cash flowFY 2025 · to 31 Dec 2025−$10.8M

Analyst forecasts

No analyst forecasts yet.